NERV · Minerva Neurosciences, Inc.
$4.58
+0.66 (+16.84%)
At close · Aug 14
Market Cap
$218.68M
Shares
47.75M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Anthony Aliquo | Chief Accounting Officer and principal accounting officer | Appointed | 2026-08-12 |
| James O’Connor | Chief Business Officer and General Counsel | Appointed | 2026-04-02 |
| Geoffrey Race | Director of Mind-NRG | Resigned | 2026-04-02 |
| Inderjit Kaul | Director | Appointed | 2025-12-22 |
| Fouzia Laghrissi-Thode | Director | Appointed | 2025-12-22 |
| Inderjit Kaul, M.D., MPH | director | Appointed | 2025-11-19 |
| Jeryl Hilleman | Chair of the Audit Committee | Resigned | 2024-05-30 |
| Jeryl Hilleman | member of the Board | Resigned | 2024-05-30 |
| Hans Peter Hasler | member of the Audit Committee | Appointed | 2023-05-05 |
| Fouzia Laghrissi-Thode, M.D. | Chair of the Compensation Committee | Appointed | 2023-05-05 |
| William Doyle | member of the Board | Resigned | 2023-05-05 |
Key facts
CIK
1598646
CUSIP
603380205
13F (30d)
57 filings
55 filers
Visit website
Investor relations